Evidence map›Paper›PMID 37037284›Full record

ArticleThe American journal of pathology2023

Identification of Spatial Proteomic Signatures of Colon Tumor Metastasis: A Digital Spatial Profiling Approach.

Joshua J Levy, John P Zavras, Eren M Veziroglu, Mustafa Nasir-Moin, Fred W Kolling, Brock C Christensen, Lucas A Salas, Rachael E Barney, Scott M Palisoul, Bing Ren and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Spatial architecture of development and disease.Nature reviews. Genetics · 2026
    Review
  4. Spatial proteomics: technical evolution and applications in cancer research.Frontiers in cell and developmental biology · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Spatially Resolved, Multiregion Proteomics for Prediction of Immunotherapy Outcome in Deficient Mismatch Repair Metastatic Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Joshua J LevyEmerging Diagnostic and Investigative Technologies, Department of Pathology and Laboratory Medicine, Dartmouth Health, Lebanon, New Hampshire; Department of Dermatology, Dartmouth Health, Lebanon, New Hampshire; Department of Epidemiology, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire; Program in Quantitative Biomedical Sciences, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire. Electronic address: joshua.j.levy@dartmouth.edu.
John P ZavrasDartmouth College, Hanover, New Hampshire.
Eren M VezirogluDartmouth College Geisel School of Medicine, Hanover, New Hampshire.
Mustafa Nasir-MoinHarvard Medical School, Cambridge, Massachusetts.
Fred W KollingDartmouth Cancer Center, Lebanon, New Hampshire.
Brock C ChristensenDepartment of Epidemiology, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire; Department of Molecular and Systems Biology, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire; Department of Community and Family Medicine, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire.
Lucas A SalasDepartment of Epidemiology, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire; Department of Molecular and Systems Biology, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire; Integrative Neuroscience at Dartmouth Graduate Program, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire.
Rachael E BarneyEmerging Diagnostic and Investigative Technologies, Department of Pathology and Laboratory Medicine, Dartmouth Health, Lebanon, New Hampshire.
Scott M PalisoulEmerging Diagnostic and Investigative Technologies, Department of Pathology and Laboratory Medicine, Dartmouth Health, Lebanon, New Hampshire.
Bing RenEmerging Diagnostic and Investigative Technologies, Department of Pathology and Laboratory Medicine, Dartmouth Health, Lebanon, New Hampshire.
Xiaoying LiuEmerging Diagnostic and Investigative Technologies, Department of Pathology and Laboratory Medicine, Dartmouth Health, Lebanon, New Hampshire.
Darcy A KerrEmerging Diagnostic and Investigative Technologies, Department of Pathology and Laboratory Medicine, Dartmouth Health, Lebanon, New Hampshire.
Kelli B PointerSection of Radiation Oncology, Department of Medicine, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire.
Gregory J TsongalisEmerging Diagnostic and Investigative Technologies, Department of Pathology and Laboratory Medicine, Dartmouth Health, Lebanon, New Hampshire. Electronic address: gregory.j.tsongalis@hitchcock.org.
Louis J VaickusEmerging Diagnostic and Investigative Technologies, Department of Pathology and Laboratory Medicine, Dartmouth Health, Lebanon, New Hampshire.
Dartmouth College · USDartmouth HealthDartmouth–Hitchcock Medical Center · USDartmouth Psychiatric Research Center · USHarvard University · US

Funding

Zhao - Proj 2P20GM130454 · NIGMS · DARTMOUTH COLLEGE · PI MICHAEL L WHITFIELD · 2019 to 2026
$27.2M
Relation Between In-utero Vitamin D and Immune Function in Early Childhood P20GM104416 · NIGMS · DARTMOUTH COLLEGE · PI SALAS DIAZ, LUCAS A · 2013 to 2022
$23.7M
DNA-based Immune Phenotyping in HNSCC for Biomarkers of Response to ImmunotherapyR01CA253976 · NCI · BROWN UNIVERSITY · PI CHRISTENSEN, BROCK C, KELSEY, KARL TIMOTHY · 2021 to 2025
$3.3M
(PQ3) Immune epigenetic biomarkers of bladder cancer outcomesR01CA216265 · NCI · DARTMOUTH COLLEGE · PI CHRISTENSEN, BROCK CLARKE · 2017 to 2021
$2.9M
Acquisition of the NextSeq2000 Sequencing platform to Increase Next Generation Sequencing Throughput While Reducing Costs at DartmouthS10OD030242 · OD · DARTMOUTH COLLEGE · PI KOLLING IV, FRED W · 2021 to 2021
$321k
NCI NIH HHS R01 CA216265NCI NIH HHS R01 CA253976NIGMS NIH HHS P20 GM104416NIGMS NIH HHS P20 GM130454NIH HHS S10 OD030242
6 · The paper itself

Abstract

Over 150,000 Americans are diagnosed with colorectal cancer (CRC) every year, and annually >50,000 individuals are estimated to die of CRC, necessitating improvements in screening, prognostication, disease management, and therapeutic options. CRC tumors are removed en bloc with surrounding vasculature and lymphatics. Examination of regional lymph nodes at the time of surgical resection is essential for prognostication. Developing alternative approaches to indirectly assess recurrence risk would have utility in cases where lymph node yield is incomplete or inadequate. Spatially dependent, immune cell-specific (eg, tumor-infiltrating lymphocytes), proteomic, and transcriptomic expression patterns inside and around the tumor-the tumor immune microenvironment-can predict nodal/distant metastasis and probe the coordinated immune response from the primary tumor site. The comprehensive characterization of tumor-infiltrating lymphocytes and other immune infiltrates is possible using highly multiplexed spatial omics technologies, such as the GeoMX Digital Spatial Profiler. In this study, machine learning and differential co-expression analyses helped identify biomarkers from Digital Spatial Profiler-assayed protein expression patterns inside, at the invasive margin, and away from the tumor, associated with extracellular matrix remodeling (eg, granzyme B and fibronectin), immune suppression (eg, forkhead box P3), exhaustion and cytotoxicity (eg, CD8), Programmed death ligand 1-expressing dendritic cells, and neutrophil proliferation, among other concomitant alterations. Further investigation of these biomarkers may reveal independent risk factors of CRC metastasis that can be formulated into low-cost, widely available assays.

Indexed as

Colonic NeoplasmsColorectal NeoplasmsBiomarkersBiomarkers, TumorHumansLymph NodesLymphocytes, Tumor-InfiltratingProteomicsTumor MicroenvironmentBiomarkersBiomarkers, Tumor

Identifiers

PMID37037284
PMCPMC10284031
OpenAlexW4362723498

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.